New test aims to personalize breast cancer care
NCT ID NCT06723990
Summary
This study is observing how a new genomic test called HER2DX affects the decisions doctors make for patients with early-stage HER2-positive breast cancer. It will see if the test helps doctors choose the best type and timing of drug therapy with more confidence. The study is not testing a new treatment, but rather how a new diagnostic tool is used in real-world medical decisions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituto Europeo di Oncologia
RECRUITINGMilan, Italy, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.